Lymphoma & Plasma Cell Disorders
News
Alisertib shows activity in non-Hodgkin lymphoma
Key clinical point: Alisertib has shown significant antitumor activity in patients with relapsed or refractory peripheral T-cell non-Hodgkin...
Conference Coverage
Combo delays progression in relapsed CLL
VIENNA—Results of the COMPLEMENT 2 trial indicate that adding ofatumumab to treatment with fludarabine and cyclophosphamide (OFC) can improve some...
Conference Coverage
EHA: Inotuzumab rallies against refractory/relapsed ALL
Key clinical point: Inotuzumab ozagamicin shows promise as a new treatment option for relapsed or refractory acute lymphoblastic leukemia. Major...
Conference Coverage
EHA: Dasatinib gets early edge over imatinib in CML
Key clinical point: Dasatinib provides more molecular responses than imatinib, but no survival advantage at 2 years in the first-line treatment of...
News
Viral protein protects EBV-infected B cells
expresses the ligand (red) that activates NKG2D, while uninfected cells (blue) do not Benjamin Chaigne-Delalande A study published in PLOS...
Video
VIDEO: Pacritinib safe with thrombocytopenia in myelofibrosis
News
Harnessing immune defense to treat Candida infection
An upset in the body’s natural balance of gut bacteria that may lead to life-threatening bloodstream infections can be reversed by enhancing an...
Conference Coverage
CAR T-cell therapy seems feasible for NHL, MM
©ASCO/Rodney White CHICAGO—The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin...
News
Follow-up PET/CT has ‘clinical value’ in NHL
BALTIMORE—Post-treatment PET/CT scans may be necessary for some patients with non-Hodgkin lymphoma (NHL), according to a presentation at the 2015...
Conference Coverage
Carfilzomib/dex doubles PFS of relapsed myeloma
Key clinical point: In a head-to-head trial, carfilzomib/dexamethasone doubled progression-free survival (PFS) compared with bortezomib/...
News
CD8 cell dose predicts outcomes in allogeneic stem cell transplantation with reduced-intensity conditioning
Key clinical point: High CD8 cell dose in peripheral blood stem cell grafts was associated with reduced risk of relapse and increased survival in...